Cantel Medical Corp. (NYSE:CMD) has received an average broker rating score of 2.00 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. Cantel Medical Corp.’s rating score has improved by 14.2% from 90 days ago as a result of various analysts’ ratings changes.

Brokers have set a one year consensus price target of $100.00 for the company and are predicting that the company will post $0.52 EPS for the current quarter, according to Zacks. Zacks has also given Cantel Medical Corp. an industry rank of 157 out of 265 based on the ratings given to related companies.

Several research firms have recently weighed in on CMD. Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Wednesday, August 2nd. Zacks Investment Research raised shares of Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a report on Tuesday, August 1st. Benchmark Co. lowered shares of Cantel Medical Corp. from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a report on Thursday, June 8th.

In related news, Chairman Charles M. Diker sold 35,000 shares of the stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $75.52, for a total value of $2,643,200.00. Following the sale, the chairman now directly owns 3,114,520 shares in the company, valued at approximately $235,208,550.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Charles M. Diker sold 13,000 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $76.36, for a total transaction of $992,680.00. Following the completion of the sale, the chairman now owns 3,124,222 shares in the company, valued at $238,565,591.92. The disclosure for this sale can be found here. Company insiders own 14.90% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Capstone Asset Management Co. bought a new stake in shares of Cantel Medical Corp. during the second quarter valued at approximately $690,000. Bank of Montreal Can bought a new stake in shares of Cantel Medical Corp. during the second quarter valued at approximately $248,000. GW&K Investment Management LLC bought a new stake in shares of Cantel Medical Corp. during the second quarter valued at approximately $30,121,000. Pennsylvania Trust Co bought a new stake in shares of Cantel Medical Corp. during the second quarter valued at approximately $6,590,000. Finally, State of Alaska Department of Revenue bought a new stake in shares of Cantel Medical Corp. during the second quarter valued at approximately $558,000. Institutional investors and hedge funds own 83.66% of the company’s stock.

WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/14/zacks-cantel-medical-corp-cmd-given-100-00-average-target-price-by-brokerages.html.

Shares of Cantel Medical Corp. (NYSE CMD) opened at 73.79 on Monday. Cantel Medical Corp. has a 1-year low of $68.19 and a 1-year high of $88.81. The stock has a market cap of $3.06 billion, a P/E ratio of 43.66 and a beta of 1.23. The company’s 50-day moving average is $75.90 and its 200 day moving average is $76.88.

Cantel Medical Corp. (NYSE:CMD) last posted its earnings results on Thursday, June 8th. The company reported $0.51 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.51. Cantel Medical Corp. had a net margin of 9.50% and a return on equity of 17.75%. The business had revenue of $192.10 million for the quarter, compared to analyst estimates of $193.84 million. The company’s revenue was up 10.6% on a year-over-year basis. Equities research analysts anticipate that Cantel Medical Corp. will post $2.06 EPS for the current year.

The company also recently declared a semiannual dividend, which was paid on Monday, July 31st. Investors of record on Monday, July 17th were given a $0.07 dividend. The ex-dividend date was Thursday, July 13th. This represents a dividend yield of 0.18%. Cantel Medical Corp.’s dividend payout ratio is 8.28%.

About Cantel Medical Corp.

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Get a free copy of the Zacks research report on Cantel Medical Corp. (CMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.